Due to equipment consolidation, MNG will discontinue testing for phenylalanine loading.
Alternative diagnostic testing is available at MNG for diagnosing dopa-responsive dystonia, characterized by GTP cyclohydrolase I (GTPCH) deficiency or sepiapterin reductase (SR) deficiency; see the Dopa-Responsive Dystonia NGS Panel (NGS446) or Comprehensive Dystonia NGS Panel (NGS358).
MNG will discontinue MET09 in plasma; testing will not be performed on samples received after 11/10/2020.
Effective July 27, 2020 the MNG amino acid assays, Test Codes MET01, MET02, and MET03 will be performed by our Parent company, LabCorp, in its Burlington, NC laboratory.
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.